Additional Supporting Information may be found in the online version of this article.

STEM_711_sm_SuppFig1A-F.tif599KSupporting Information Figures 1 A to F
STEM_711_sm_SuppFig1G-N.tif337KSupporting Information Figures 1 G to N
STEM_711_sm_SuppFig2.tif2376KSupporting Information Figure 2
STEM_711_sm_SuppFig3.tif4583KSupporting Information Figure 3
STEM_711_sm_SuppFig4.tif246KSupporting Information Figure 4
STEM_711_sm_SuppTable1.doc46KTable S.1. CD133 Expression as Prognostic Marker in Uterine Carcinosarcoma Patients; Patient Characteristics
STEM_711_sm_SuppTable2.doc126KTable S.2. Stemness- and ES Cell-Related Genes Showing More Than 2-fold Changes in Expression in CD133+ Cells Compared to CD133- cells Table S.2.
STEM_711_sm_SuppTable3.doc81KTable 3a. Gene Signaling Pathways Upregulated in CD133− Cells p<0.05
STEM_711_sm_SuppTable4.doc33KTable S.4. In Vivo Tumorigenicity of CD133+ and CD133− Cells
STEM_711_sm_SuppInfo.doc53KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.